Sonnet Biotherapeutics Holdings Inc (SONN)
Official siteBIOTECHNOLOGY
Last updated: Dec 02, 2025 at 4:00 PM ET
Sonnet Biotherapeutics Holdings Inc (SONN) Financials: Revenue, Profit and Cash Flow
Sonnet Biotherapeutics Holdings reported revenue of $1.00M for the fiscal year ended Sep 30, 2025, up 5268.8% from the year before. That year, net income was -$16.11M with a net margin of -1611.3%, operating cash flow was -$12.83M and free cash flow was -$12.83M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$3.78M.
Revenue and Margins
Over the 9 years to Sep 2025, revenue fell from $41.70M, a compound annual decline of 33.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $1.00M | +5268.8% | N/A | -1584.4% | -1611.3% |
| Sep 2024 | $18.63K | -87.4% | 100.0% | -63617.9% | -39929.3% |
| Sep 2023 | $147.81K | -57.8% | 100.0% | -12714.5% | -12741.6% |
| Sep 2022 | $349.94K | -27.6% | -6027.9% | -8478.3% | -8508.3% |
| Sep 2021 | $483.63K | N/A | 100.0% | -5187.4% | -5170.5% |
| Sep 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $40.61M | N/A | 80.5% | -11.6% | -12.4% |
| Sep 2019 | $40.61M | N/A | 80.5% | -11.6% | -12.0% |
| Sep 2017 | $41.43M | -0.6% | 4.9% | -6.1% | -16.4% |
| Sep 2016 | $41.70M | N/A | 8.0% | -6.3% | -21.8% |
Income Statement
In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Dec 2019 | Sep 2019 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00M | $18.63K | $147.81K | $349.94K | $483.63K | $0 | $40.61M | $40.61M | $41.43M | $41.70M |
| Cost of revenue | N/A | $83.11K | $75.75K | $93.26K | $95.16K | $58.31K | $7.93M | $7.93M | $39.41M | $38.38M |
| Gross profit | N/A | $18.63K | $147.81K | -$21.09M | $483.63K | -$58.31K | $32.68M | $32.68M | $2.03M | $3.33M |
| Research and development | $8.36M | $5.74M | $11.81M | $21.44M | $16.63M | $9.88M | $2.20M | $2.20M | $0 | $0 |
| Operating income | -$15.84M | -$11.85M | -$18.79M | -$29.67M | -$25.09M | -$17.41M | -$4.71M | -$4.71M | -$2.52M | -$2.62M |
| Net income | -$16.11M | -$7.44M | -$18.83M | -$29.77M | -$25.01M | -$24.27M | -$5.03M | -$4.87M | -$6.79M | -$9.08M |
| EBITDA | -$15.84M | -$11.77M | -$18.72M | -$29.58M | -$24.99M | N/A | -$2.54M | N/A | N/A | $541.15K |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.00M | $104.39K | $0 | $0 | $18.63K | $37.26K | $36.85K | $36.45K | $37.26K | $62.75K |
| Gross profit | -$22.16K | -$22.09K | -$886.08K | -$21.61K | -$21.04K | -$20.50K | -$1.35K | $17.79K | $17.87K | $17.57K | $18.82K | $44.83K |
| Operating income | -$3.81M | -$4.23M | -$2.85M | -$3.17M | -$3.53M | -$3.87M | -$1.28M | -$3.60M | -$3.92M | -$5.66M | -$5.61M | -$7.38M |
| Net income | -$3.78M | -$3.49M | -$3.16M | -$3.13M | -$3.51M | $365.43K | -$1.17M | -$3.68M | -$3.95M | -$5.67M | -$5.54M | -$7.49M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of $46.57K by $5.07M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Dec 2018 | Sep 2018 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.88M | $2.77M | $5.43M | $5.83M | $28.99M | $7.99M | $39.75K | $29.79M | N/A | $30.18M |
| Current assets | $14.34M | $2.12M | $4.74M | $5.41M | $28.81M | $7.64M | $39.75K | $1.34M | N/A | $1.80M |
| Cash and equivalents | $5.12M | $149.46K | $2.27M | $3.05M | $27.62M | $7.35M | $35.65K | $524.11K | N/A | $438.49K |
| Total liabilities | $4.10M | $3.26M | $5.66M | $8.37M | $6.73M | $4.97M | $2.89M | $21.54M | N/A | $18.69M |
| Short-term debt | $46.57K | $84.29K | $146.10K | $52.08K | $95.27K | $103.24K | $217.38K | N/A | N/A | $8.74M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $124.88K | $709.70K | $3.00M | N/A | $212.26K |
| Shareholder equity | $10.79M | -$485.74K | -$225.98K | -$2.54M | $22.26M | $3.02M | -$2.85M | $7.43M | N/A | $10.71M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.88M | $2.06M | $3.84M | $7.18M | $2.77M | $5.80M | $5.91M | $5.34M | $5.43M | $10.03M | $13.31M | $4.94M |
| Total liabilities | $4.10M | $5.10M | $3.17M | $3.15M | $3.26M | $3.18M | $2.86M | $2.77M | $5.66M | $6.62M | $7.94M | $8.48M |
| Cash and equivalents | $5.12M | $321.30K | $2.06M | $4.86M | $149.46K | $3.55M | $3.79M | $3.02M | $2.27M | $7.02M | $11.39M | $1.70M |
| Shareholder equity | $10.79M | -$3.05M | $662.26K | $4.04M | -$485.74K | $2.62M | $3.05M | $2.57M | -$225.98K | $3.42M | $5.37M | -$3.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Dec 2019 | Sep 2019 | Sep 2018 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.83M | -$8.61M | -$21.34M | -$27.69M | -$22.55M | -$15.61M | -$2.23M | -$2.23M | -$672.06K | -$724.43K |
| Capital expenditures | $0 | $3 | $443.25K | $896.48K | $3.62K | $76.18K | $2.39M | $2.39M | $0 | $1.63M |
| Free cash flow | -$12.83M | -$8.61M | -$21.79M | -$28.58M | -$22.56M | -$15.69M | -$4.62M | -$4.62M | -$672.06K | -$2.35M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $142.22K | N/A | N/A |
| Investing cash flow | -$12.00K | -$12.00K | -$443.25K | -$896.48K | -$3.62K | -$76.18K | $678.67K | -$2.44M | $118.01K | -$439.30K |
| Financing cash flow | $26.05M | $6.49M | $21.01M | $4.01M | $42.83M | $23.01M | $2.26M | $2.26M | N/A | $1.36M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.76M | -$2.47M | -$2.91M | -$3.17M | -$3.07M | $723.79K | -$3.09M | -$4.56M | -$6.17M | -$4.70M | -$5.92M |
| Capital expenditures | $0 | $0 | $0 | $0 | $12.00K | $0 | $3 | $170.00K | $12.00K | $261.25K | $0 |
| Free cash flow | -$1.76M | -$2.47M | -$2.91M | -$3.17M | -$3.08M | $723.79K | -$3.09M | -$4.73M | -$6.18M | -$4.96M | -$5.92M |
Frequently Asked Questions About SONN
What is Sonnet Biotherapeutics Holdings' annual revenue?
Sonnet Biotherapeutics Holdings reported revenue of $1.00M for the fiscal year ended Sep 30, 2025.
How fast is Sonnet Biotherapeutics Holdings' revenue growing?
Revenue was up 5268.8% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 41.9%.
Is Sonnet Biotherapeutics Holdings profitable?
No. Sonnet Biotherapeutics Holdings reported net income of -$16.11M for the fiscal year ended Sep 30, 2025, with a net margin of -1611.3%.
How much free cash flow does SONN generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$12.83M minus capital expenditures of $0 produced free cash flow of -$12.83M.
How much debt does Sonnet Biotherapeutics Holdings have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $46.57K and cash and equivalents of $5.12M.
SONN pages: Overview, Financials